Loading…
ProQR Therapeutics N.V. is projected to rise to $1.80 by 2027, a +5% move from its current price of $1.72. PRQR is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/2/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 3 | $1.66 | $1.72 | $1.79 | 0.00% |
| Aug 4 | $1.63 | $1.72 | $1.82 | -0.01% |
| Aug 5 | $1.61 | $1.72 | $1.84 | -0.01% |
| Aug 6 | $1.59 | $1.72 | $1.86 | -0.01% |
| Aug 7 | $1.58 | $1.72 | $1.87 | -0.01% |
| Aug 8 | $1.57 | $1.72 | $1.89 | -0.02% |
| Aug 9 | $1.55 | $1.72 | $1.90 | -0.02% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.55 | $1.72 | $1.90 | -0.02% |
| Week 2 | $1.49 | $1.72 | $1.98 | -0.04% |
| Week 3 | $1.44 | $1.72 | $2.05 | -0.06% |
| Week 4 | $1.40 | $1.72 | $2.11 | -0.08% |
| Week 5 | $1.37 | $1.72 | $2.16 | -0.10% |
| Week 6 | $1.34 | $1.72 | $2.20 | -0.12% |
| Week 7 | $1.31 | $1.72 | $2.25 | -0.15% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
ProQR Therapeutics N.V. is a clinical-stage biotechnology company focused on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs.
Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic diseases. The company also develops AX-2402, which targets methyl CpG binding protein 2 mutations for Rett syndrome; AX-2911, which targets PNPLA3 for metabolic dysfunction-associated steatohepatitis; and AX-1412, which targets the B4GALT1 gene for cardiovascular diseases. It has a research and collaboration agreement with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system.
The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
ProQR Therapeutics N.V. trades under the symbol PRQR. The current price is $1.72, and the company has a market capitalization of $242.73M. It ranks 3461 by market cap. The forecasted price outlook shows multi-year upside, with the average price rising from $1.72 in 2026 to $2.74 by 2030 and up to $11.98 on average by 2050, with corresponding max forecasts reaching $27.12 by 2050.
The 30-day technical setup supports a constructive view, with a broad range of potential movement ahead of those long-run projections.
A major floor 21.3% below — a decisive break under it would weaken the trend.
The nearest floor, 11.0% below — buyers have tended to step in here.
The nearest ceiling, 9.9% above — a clean break opens room to run.
A major ceiling 20.5% above — clearing it would confirm fresh momentum.
Key PRQR support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PRQR market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.74 | Sell | $1.75 | Sell |
| MA 10 | $1.77 | Sell | $1.75 | Sell |
| MA 20 | $1.74 | Sell | $1.74 | Sell |
| MA 50 | $1.65 | Buy | $1.70 | Buy |
| MA 100 | $1.67 | Buy | $1.70 | Buy |
| MA 200 | $1.84 | Sell | $1.79 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 49.57 | Neutral |
| Stoch RSI (14) | 4.32 | Buy |
| CCI (20) | -30.68 | Neutral |
| Williams %R (14) | -76.19 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | -2.82 | Sell |
| Bollinger %B (20,2) | 0.41 | Neutral |
| Stochastic %K (14) | 23.81 | Neutral |
| TRIX (15) | 0.25 | Buy |
| Awesome (5,34) | 0.02 | Buy |
| Ultimate (7,14,28) | 40.27 | Neutral |
| Momentum (10) | 0.02 | Buy |
| Aroon Osc (25) | 64.00 | Buy |
| Hull MA (9) | 1.74 | Sell |
| ADX (14) | 7.15 | Neutral |
| ATR (14) | 0.06 | Info |
The 30-day technical picture is described as bullish. The RSI(14) is at 50, placing momentum in a neutral zone despite positive sentiment. The stock trades near the SMA50 of $1.64 and the SMA200 of $1.86, suggesting a price that sits between short- and longer-term moving averages.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.37 | $1.72 | $2.36 | 0% | Neutral | |
| $1.39 | $1.80 | $2.51 | +5% | Neutral | |
| $1.48 | $2.00 | $2.93 | +16% | Neutral | |
| $1.86 | $2.62 | $3.98 | +52% | Bullish | |
| $2.01 | $2.90 | $4.56 | +69% | Bullish | |
| $2.27 | $3.39 | $5.47 | +97% | Bullish | |
| $2.32 | $3.56 | $5.89 | +107% | Bullish | |
| $2.05 | $3.22 | $5.46 | +87% | Bullish | |
| $2.20 | $3.54 | $6.12 | +106% | Bullish | |
| $2.41 | $3.97 | $6.99 | +131% | Bullish | |
| $3.21 | $5.89 | $11.21 | +243% | Bullish | |
| $6.14 | $13.65 | $29.02 | +694% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.37 | $1.72 | $2.18 | +0.00% |
| September 2026 | $1.49 | $1.78 | $2.21 | +3.74% |
| October 2026 | $1.42 | $1.72 | $2.16 | -3.87% |
| November 2026 | $1.44 | $1.75 | $2.23 | +2.08% |
| December 2026 | $1.49 | $1.83 | $2.36 | +4.64% |
Click any year to see its month-by-month PRQR forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect PRQR to range from $1.37 to $2.36 through 2026. The $1.72 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The PRQR price prediction for 2027 points to an average of $1.80 (low $1.39, high $2.51) — a potential gain of +5% on today's $1.72. A consolidation phase looks the most probable path here.
In 2028, PRQR is projected to trade between $1.48 and $2.93, averaging $2.00 — a potential gain of +16% from today's $1.72. That is up +11% on the projected 2027 average. Price action looks broadly range-bound.
ProQR Therapeutics N.V.'s 2029 outlook centres on $2.62, within a $1.86 to $3.98 range. That is up +31% on the projected 2028 average. That marks a +52% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, PRQR could reach as high as $4.56, with a base case around $2.90 and support toward $2.01 — roughly +69% from $1.72. Momentum favours further upside here.
Expect PRQR to range from $2.27 to $5.47 through 2031. The $3.39 average target implies a +97% move from current prices. That is up +17% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The PRQR price prediction for 2032 points to an average of $3.56 (low $2.32, high $5.89) — a potential gain of +107% on today's $1.72. Momentum favours further upside here.
In 2033, PRQR is projected to trade between $2.05 and $5.46, averaging $3.22 — a potential gain of +87% from today's $1.72. That is -9% versus the projected 2032 average. Buyers look set to stay in control over this stretch.
ProQR Therapeutics N.V.'s 2034 outlook centres on $3.54, within a $2.20 to $6.12 range. That is up +10% on the projected 2033 average. That marks a +106% change versus current levels. Momentum favours further upside here.
By 2035, PRQR could reach as high as $6.99, with a base case around $3.97 and support toward $2.41 — roughly +131% from $1.72. Buyers look set to stay in control over this stretch.
Expect PRQR to range from $3.21 to $11.21 through 2040. The $5.89 average target implies a +243% move from current prices. That is up +48% on the projected 2035 average. Momentum favours further upside here.
The PRQR price prediction for 2050 points to an average of $13.65 (low $6.14, high $29.02) — a potential gain of +694% on today's $1.72. Buyers look set to stay in control over this stretch.
Investing $1,000 in PRQR today (≈ 581.395349 PRQR) could be worth
$7,937.11
+$6,937.11 (+694%) by 2050 · US Dollar
Based on the average projected PRQR price of $13.65 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PRQRwould be worth at today's price.
$1,000 invested in PRQR on Jul 31, 2025 (≈ 476.190498 PRQR) would be worth
$819.05
-$180.95 (-18.1%) today · 0.82× · US Dollar
Based on a PRQR entry price of $2.1 vs. today's $1.72.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.72 | $1,000 | -0.0% |
| 1 month ago | $1.75 | $982.86 | -1.7% |
| 3 months ago | $1.55 | $1,109.68 | +11.0% |
| 6 months ago | $1.55 | $1,109.68 | +11.0% |
| 1 year ago | $2.1 | $819.05 | -18.1% |
| All time (5.0y) ago | $5.8 | $296.55 | -70.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PRQR forecast.
Our base-case forecast reaches $3.40 around 2032.
Implied market cap at $3.40: $479.81M
The multi-year forecast points to meaningful upside over the coming years. By 2029 the average price is projected to $2.48 with a min of $1.71 and a max of $3.90 (ROI 44) and sentiment turning bullish. By 2030 the average is $2.74 (min $1.82, max $4.46; ROI 59.1) and by 2031 the average rises to $3.25 (min $2.09, max $5.47; ROI 89.1).
The trajectory continues with 2032 at $3.33 (min $2.07, max $5.75; ROI 93.5), 2033 at $2.88 (min $1.74, max $5.09; ROI 67.5), 2034 at $3.25 (min $1.90, max $5.87; ROI 88.8), and 2035 at $3.56 (min $2.03, max $6.56; ROI 106.7). The long-range view extends to 2040 with an average of $5.28 (min $2.63, max $10.61; ROI 207.1) and to 2050 with an average of $11.98 (min $5.39, max $27.12; ROI 596.5). These figures imply bullish momentum over the longer horizon, while noting that these are estimates, not guarantees, and subject to risk and uncertainty.
Tap a question to reveal the answer.
2030: min $1.82, avg $2.74, max $4.46; ROI 59.1; sentiment BULLISH.
Forecasts show upside potential with 2030 avg $2.74 and 2050 avg $11.98, with ROI values of 59.1 (2030) and 596.5 (2050). These are estimates, not guarantees.
Yes, the 2030 max is $4.46, indicating the possibility of exceeding $4.00 within that year.
Current price is $1.72 and market cap is $242.73M; the rank is 3461.
The 30-day range is $1.29 to $2.30.
ProQR Therapeutics N.V. Community Discussion
0Share your ProQR Therapeutics N.V. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.